30.47
Schlusskurs vom Vortag:
$30.95
Offen:
$30.85
24-Stunden-Volumen:
601.85K
Relative Volume:
0.75
Marktkapitalisierung:
$2.85B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.1689
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-4.27%
1M Leistung:
+1.03%
6M Leistung:
-21.16%
1J Leistung:
-43.13%
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRNX
Crinetics Pharmaceuticals Inc
|
30.47 | 2.98B | 4.72M | -277.91M | -203.56M | -3.73 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Eingeleitet | Goldman | Neutral |
2025-03-25 | Eingeleitet | Stifel | Buy |
2025-02-11 | Eingeleitet | TD Cowen | Buy |
2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
2024-03-06 | Eingeleitet | Citigroup | Buy |
2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
2023-12-21 | Eingeleitet | Jefferies | Hold |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-12-23 | Eingeleitet | ROTH Capital | Buy |
2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
2018-08-13 | Eingeleitet | JP Morgan | Neutral |
2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
What drives Crinetics Pharmaceuticals Inc. stock priceRapidly growing investment returns - jammulinksnews.com
What analysts say about Crinetics Pharmaceuticals Inc. stockStrong return on assets - jammulinksnews.com
Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders - BioWorld MedTech
Crinetics stock rating reiterated by Piper Sandler ahead of PALSONIFY PDUFA - Investing.com Canada
H.C. Wainwright reiterates Buy rating on Crinetics stock at $81 price target - Investing.com UK
Crinetics Pharmaceuticals’ Palsonify Gains Positive Endorsement for Acromegaly Treatment with Promising Pipeline Expansion - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Arizona State Retirement System - Defense World
Is Crinetics Pharmaceuticals Inc. a good long term investmentPowerful growth strategies - PrintWeekIndia
The week in pharma: action, reaction and insight – week to July 18 - The Pharma Letter
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Xponance Inc. - Defense World
Crinetics Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity gains - jammulinksnews.com
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - MSN
Crinetics Pharmaceuticals’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada
How Crinetics Pharmaceuticals Inc. stock performs during market volatilityFree Signals Group - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser
What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Community - Newser
JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria
Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - inkl
Crinetics reveals new data from acromegaly therapy programme - Yahoo Finance
New data for oral acromegaly drug ahead of approval decision - The Pharma Letter
Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest
Crinetics Pharmaceuticals New Data Show Durable Control of Palsonify in Acromegaly - MarketScreener
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News - GuruFocus
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - The Manila Times
Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative
Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study - Stock Titan
Crinetics to Present New Long-Term Data Demonstrating Durable Co - GuruFocus
Amalgamated Bank Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
The Goldman Sachs Group Initiates Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financia - GuruFocus
Crinetics Earnings: Q2 2025 Results and Conference Call Scheduled for August 7 After Market Close - Stock Titan
Goldman Sachs initiates coverage on Crinetics stock with Neutral rating By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants - GuruFocus
Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation - Stock Titan
Goldman Sachs Initiates Crinetics Pharmaceuticals at Neutral With $36 Price Target - MarketScreener
Goldman Sachs Begins Coverage of Crinetics (CRNX) with Neutral O - GuruFocus
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):